Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


When Approvable Is Good News: Forest Gets January Launch for Bystolic

This article was originally published in RPM Report

Executive Summary

Is there a way out of the woods for new drug sponsors seeking FDA approval for products with broad primary care indications? Forest may have found a path with nebivolol, but the formula is not one that will excite many other drug sponsors.

You may also be interested in...

A REMS by any Other Name

A new prescription drug for treatment of varicose veins clears FDA. The only dispute in the review: how to handle a remote but real risk of anaphylaxis. A REMS? Not this time…

The Data Everybody's Talking About: Proof FDA is More Conservative?

Approval letters are down, "approvable" and "non-approvable" letters are up. "Black box" warnings have seen a four-fold increase over the last five years. Biopharma executives are now drawing their own conclusions about the state of FDA regulation-based on the numbers.

Straight Talk from FDA: Wyeth R&D Head Reacts to Climate Change for NDA/BLA Reviews

Wyeth has had some tough times with FDA on its current crop of NDAs.Those experiences sent a team of senior execs down to FDA to find out what is up at the agency. What the execs heard was a call to action. The meeting "caused us at Wyeth to realize that we have to find a different way to operate." The current series of delays and rejections for important new drug applications is not a temporary situation for companies to ride out, but rather a sign of new regulatory

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts